Allarity Therapeutics, Inc. (ALLR)
NASDAQ: ALLR · Real-Time Price · USD
1.410
+0.030 (2.17%)
At close: Aug 28, 2026, 4:00 PM EDT
1.410
0.00 (0.00%)
After-hours: Aug 28, 2026, 4:10 PM EDT
Allarity Therapeutics Employees
As of December 31, 2025, Allarity Therapeutics had 8 total employees, including 7 full-time and 1 part-time employees. The number of employees increased by 1 or 14.29% compared to the previous year.
Employees
8
Change (1Y)
1
Growth (1Y)
14.29%
Revenue / Employee
$43,125
Profits / Employee
-$1,541,750
Market Cap
22.43M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 8 | 1 | 14.29% | 7 | 1 |
| Dec 31, 2024 | 7 | 1 | 16.67% | 6 | 1 |
| Dec 31, 2023 | 6 | -3 | -33.33% | 5 | 1 |
| Dec 31, 2022 | 9 | -4 | -30.77% | 9 | 0 |
| Dec 31, 2021 | 13 | -1 | -7.14% | 13 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Longeveron | 38 |
| Cerenome | 28 |
| Jasper Therapeutics | 22 |
| CalciMedica | 16 |
| Tvardi Therapeutics | 12 |
| Cellectar Biosciences | 11 |
| Cocrystal Pharma | 10 |
| Neuphoria Therapeutics | 8 |
ALLR News
- 14 days ago - Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign - GlobeNewsWire
- 7 weeks ago - Allarity Therapeutics Announces CLIA Certification, Clearing the Path for Advancing DRP® Testing for FDA Registration - GlobeNewsWire
- 2 months ago - Allarity Therapeutics Announces the Grant of Essential U.S. Patent for Its Stenoparib DRP® Companion Diagnostic - GlobeNewsWire
- 2 months ago - Allarity to present trial-in-progress poster on Phase 2 stenoparib trial - TheFly
- 2 months ago - Allarity Therapeutics to Present Trial-in-Progress Poster on Phase 2 Stenoparib Trial at ESMO Gynaecological Cancers Congress 2026 - GlobeNewsWire
- 3 months ago - Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers - GlobeNewsWire
- 4 months ago - Allarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in Stockholm - GlobeNewsWire
- 4 months ago - Allarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing Campaign - GlobeNewsWire